Fig. 8: Delivery routes impact KT-NE biodistribution in vivo. | Nature Communications

Fig. 8: Delivery routes impact KT-NE biodistribution in vivo.

From: A nanoemulsion targeting adipose hypertrophy and hyperplasia shows anti-obesity efficiency in female mice

Fig. 8

a Schematic illustration of KT-NE administration routes (i.v., i.p., and s.c.). b Biodistribution of DIR-labeled KT-NE at 6 h, 24 h, and 48 h after indicated injection (n = 5 biologically independent mice). c Biodistribution and (d, e) relative fluorescence intensity efficiency indexes of DIR-labeled KT-NE in subcutaneous adipose tissue (SAT), visceral fat depots (VFD), heart, liver, spleen, lung and kidney of mice with obesity, after KT-NE injected (i.v., i.p., and s.c. respectively) into the hosts for 48 h. f Biodistribution and (g, h) relative fluorescence intensity efficiency indexes of DIR-labeled KT-NE in SAT (g) and VFD (h) of mice with obesity after KT-NE injected (i.v., i.p., and s.c. respectively) into the hosts for 48 h. n = 5 biologically independent animals. Source data are provided as a Source Data file. Statistical significance was evaluated by an unpaired two-tailed t-test. All data was expressed as mean ± SD.

Back to article page